Engineering the next wave of CHO performance with S-CHOice® 2G platform
As demand for advanced biologics grows, improving productivity while accelerating development timelines has become a key priority. Cell line development (CLD) plays a critical role in achieving this within modern biomanufacturing.
In this whitepaper, our scientists introduce our latest cell line technology, S-CHOice® 2G. This next generation of our proprietary CHO cell line platform retains the core strengths of its first generation, while improving productivity and supporting higher titers.
Key highlights include:
✅ Enhanced productivity across multiple mAbs through optimized platform design and process conditions
✅ Average titers >10 g/L using selected S-CHOice® 2G clones
✅ Integration with expanded in-house CLD capabilities, including upcoming vector construction services
As demand for advanced biologics grows, improving productivity while accelerating development timelines has become a key priority. Cell line development (CLD) plays a critical role in achieving this within modern biomanufacturing.
In this whitepaper, our scientists introduce our latest cell line technology, S-CHOice® 2G. This next generation of our proprietary CHO cell line platform retains the core strengths of its first generation, while improving productivity and supporting higher titers.
Key highlights include:
✅ Enhanced productivity across multiple mAbs through optimized platform design and process conditions
✅ Average titers >10 g/L using selected S-CHOice® 2G clones
✅ Integration with expanded in-house CLD capabilities, including upcoming vector construction services
Related Content